DC Circ. Ruling Dangerous For Hatch-Waxman: Takeda

By Dani Kass (August 31, 2016, 7:09 PM EDT) -- Takeda Pharmaceuticals USA Inc. and hedge funds that invested in it asked the D.C. Circuit Monday to reconsider its dismissal of their suit alleging the Food and Drug Administration violated patent protections when it approved a competing gout drug made by West-Ward Pharmaceuticals Corp., saying the decision turns Hatch-Waxman litigation on its head....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!